Cadila Healthcare Sees Large Gain In Japan From Import Duty Change
This article was originally published in PharmAsia News
Cadila Healthcare expects to be a big winner in the wake of Japan's reduction in duties on Indian generic drugs, but also is looking to The Philippines, South Africa and Mexico as other lucrative markets.
You may also be interested in...
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.
House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.